Pharma
Piramal Pharma Ltd
PPLPHARMA · NSE · INE0DK501011Monday, 26 Oct 20269:31 am
Market Cap₹25,348 Cr
P/E—
P/B3.1
EPS-₹2.37
Div Yield0.1%
ROE-4.0%
ROCE-1.4%
ROE-4.0%
1Y Return+17.46%
Avg. Volume4.6M
Price Chart
52-Week Range
About
Piramal Pharma Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap₹25,348 Cr
Current Price₹191.15
52W High / Low₹231.93 / ₹132.3
Stock P/E—
Price to Book3.1
EPS (TTM)-₹2.37
Dividend Yield0.1%
ROE-4.0%
1Y Return+17.46%
Day Change+0.04%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|---|
| Sales | ₹9,205 Cr | ₹8,869 Cr | ₹9,151 Cr | ||||
| Expenses | ₹8,195 Cr | ₹7,947 Cr | ₹7,706 Cr | ||||
| Operating Profit | ₹1,010 Cr | ₹922 Cr | ₹1,445 Cr | ||||
| OPM % | 11.0% | 10.0% | 16.0% | ||||
| Other Income | ₹86 Cr | ₹74 Cr | ₹208 Cr | ||||
| Depreciation | ₹858 Cr | ₹831 Cr | ₹816 Cr | ||||
| Interest | ₹343 Cr | ₹341 Cr | ₹422 Cr | ||||
| Profit Before Tax | ₹-104 Cr | ₹-176 Cr | ₹415 Cr | ||||
| Tax | ₹210 Cr | ₹150 Cr | ₹324 Cr | ||||
| Net Profit | ₹-314 Cr | ₹-326 Cr | ₹91 Cr | ||||
| EPS (₹) | -2.4 | -2.5 | 0.7 | ||||
| Dividend Payout % | — | 0% | 20% |
Financial history locked
Register freeRegister free to see 4 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹2,270 Cr | ₹2,752 Cr | ₹2,140 Cr | ₹2,044 Cr | |||||||||
| Expenses | ₹2,075 Cr | ₹2,291 Cr | ₹1,944 Cr | ₹1,885 Cr | |||||||||
| Operating Profit | ₹195 Cr | ₹461 Cr | ₹196 Cr | ₹159 Cr | |||||||||
| OPM % | 9.0% | 17.0% | 9.0% | 8.0% | |||||||||
| Depreciation | ₹224 Cr | ₹218 Cr | ₹213 Cr | ₹203 Cr | |||||||||
| Interest | ₹88 Cr | ₹83 Cr | ₹89 Cr | ₹82 Cr | |||||||||
| Net Profit | ₹-69 Cr | ₹-9 Cr | ₹-136 Cr | ₹-99 Cr | |||||||||
| EPS (₹) | -0.5 | -0.1 | -1.0 | -0.8 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹1,327 Cr | ₹1,324 Cr | ₹1,323 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹6,835 Cr | ₹6,801 Cr | ₹6,588 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹5,675 Cr | ₹4,856 Cr | ₹4,710 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹3,770 Cr | ₹2,448 Cr | ₹2,462 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹17,607 Cr | ₹15,429 Cr | ₹15,083 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹8,684 Cr | ₹8,133 Cr | ₹7,990 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹437 Cr | ₹291 Cr | ₹385 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹7,386 Cr | ₹6,028 Cr | ₹5,592 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹17,607 Cr | ₹15,429 Cr | ₹15,083 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 4 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹1,653 Cr | ₹-820 Cr | ₹-39 Cr | ₹794 Cr |
| FY25 | ₹892 Cr | ₹-488 Cr | ₹-441 Cr | ₹-37 Cr |
| FY24 | ₹1,005 Cr | ₹-416 Cr | ₹-422 Cr | ₹166 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 |
Cash flow history locked
Register freeRegister free to see 4 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| 3B BlackBio Dx Ltd | ₹1,210 Cr | 21.4 | +20.2% | +17.9% |
| Aarey Drugs & Pharmaceuticals Ltd | — | — | +2.75% | +59.84% |
| Aarti Drugs Ltd | ₹3,429 Cr | 18.0 | +13.37% | +11.57% |
| Aarti Pharmalabs Ltd | ₹7,495 Cr | 35.2 | +8.51% | +14.26% |
| Abbott India Ltd | — | — | +34.46% | -7.16% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-18Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating -Niche Ninety Nine Capability And Certifications (OPC) Private LimitedBSE Filing2026-08-18Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private LimitedCNW Group2026-08-04Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying SuiteCNW Group2026-08-04Piramal Pharma Ltd (BOM:543635) (Q1 2027) Earnings Call Highlights: Strong Revenue Growth and ...GuruFocus.com2026-06-22Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer AuditsCNW Group
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.